AGIO Stock Price | Agios Pharm P/E, Revenue, EPS, & Forecasts

Agios Pharm • AGIO

AGIO current price

$32.86+35.66%

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs
News

-4.06%

-44.01%

-22.96%

-25.35%

+35.66%

MAX

-71.43%

About Agios Pharm

Ticker

AGIO

Trading on

NASDAQ

ISIN

US00847X1046

Industry

Biotechnology

Sector

Healthcare

CEO

Brian M. Goff M.B.A.

Headquarters

88 Sidney Street, Cambridge, MA, United States, 02139

Employees

383

Website

agios.com

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Metrics

BasicAdvanced

Market cap

$1.88B

P/E ratio

2.83

EPS

$11.66

Dividend Yield

0.00%

Beta

0.75

Forward P/E ratio

2.47

EBIDTA

$-401M

Ex dividend date

Price & volume

Market cap

$1.88B

Average daily volume

1.2M

90-day return

-22.96%

30-day return

-44.01%

7-day return

-4.06%

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

2.83

Forward P/E

2.47

PEG ratio

Trailing P/E

2.83

Price to sales

57.31

Price to book

1.16

Earnings

EPS

$11.66

EPS estimate (current quarter)

$1.11

EPS estimate (next quarter)

-$1.73

EBITDA

$-401M

Revenues (TTM)

$32.9M

Revenues per share (TTM)

$0.58

Technicals

Beta

0.75

52-week High

$62.58

52-week Low

$20.96

50-day moving average

$48.82

200-day moving average

$42.24

Short ratio

5.92

Short %

9.10%

Management effectiveness

ROE (TTM)

53.66%

ROA (TTM)

18.18%

Profit margin

2,051.38%

Gross profit margin

$12.5M

Operating margin

1,146.93%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

21.20%

Share stats

Outstanding Shares

57M

Float

50.5M

Insiders %

1.51%

Institutions %

107.57%

Analyst Insights & forecasts

67% Buy

33% Hold

0% Sell

Based on information from 9 analysts.

Average price target

$57.29

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$1.72

-$1.65

4.24%

Q4 • 23Beat

-$1.45

-$1.65

12.12%

Q1 • 24Beat

-$1.69

-$1.60

5.63%

Q2 • 24Beat

-$2.42

$1.11

318.02%

Q3 • 24Beat

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$8.6M

$-96.1M

1,115.71%

Q2 • 24

$9M

$948M

10,574.69%

Q3 • 24

4.05%

1,086.20%

1,047.80%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$773M

$113M

14.56%

Q2 • 24

$1.79B

$165M

9.22%

Q3 • 24

131.78%

46.71%

36.70%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-72.6M

$37.2M

$1.1M

$-72.7M

Q2 • 24

$-84.2M

$251M

$2.6M

$-84.6M

Q3 • 24

16.02%

573.38%

139.95%

16.34%

QoQ growth

QuarterlyAnnual

Sentiment analysis

-1.5

Neutral

+1.5

-0.30

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Agios Pharm share?

Agios Pharm shares are currently traded for $32.86 per share.

How many shares does Agios Pharm have?

Agios Pharm currently has 57M shares.

Does Agios Pharm pay dividends?

No, Agios Pharm doesn't pay dividends.

What is Agios Pharm 52 week high?

Agios Pharm 52 week high is $62.58.

What is Agios Pharm 52 week low?

Agios Pharm 52 week low is $20.96.

What is the 200-day moving average of Agios Pharm?

Agios Pharm 200-day moving average is $42.24.

Who is Agios Pharm CEO?

The CEO of Agios Pharm is Brian M. Goff M.B.A..

How many employees Agios Pharm has?

Agios Pharm has 383 employees.

What is the market cap of Agios Pharm?

The market cap of Agios Pharm is $1.88B.

What is the P/E of Agios Pharm?

The current P/E of Agios Pharm is 2.83.

What is the EPS of Agios Pharm?

The EPS of Agios Pharm is $11.66.

What is the PEG Ratio of Agios Pharm?

The PEG Ration of Agios Pharm is 0.

What do analysts say about Agios Pharm?

According to the analysts Agios Pharm is considered a buy.

Agios Pharm news

thumbs_up_down

•Neutral

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease

CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the European Commission has adopted a positive decision for the designation of mitapivat, an oral, small molecule PK activator, as an orphan medicinal product (OMP) for the treatment of sickle cell disease. Earlier, in November 2020, the U.S. Food and Drug Administration (FDA) also granted orphan drug designation to mitapivat for sickle cell disease.

GlobeNewsWire•18 Dec 2024, 12:00

thumb_down_alt

•Negative

Here's Why Agios Stock Plummeted More Than 20% on Monday

The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.

Zacks Investment Research•10 Dec 2024, 16:50

thumb_down_alt

•Negative

Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug

Shares of Agios Pharmaceuticals collapsed Monday on an unexpected side effect related to the company's thalassemia treatment, mitapivat. The post Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug appeared first on Investor's Business Daily.

Investors Business Daily•09 Dec 2024, 17:02